ASX Cannabis Stocks in 2026: Is the risk worth the reward?

It has been a while since we’ve looked at ASX Cannabis Stocks, and we are sure we are not the only ones to have paid little attention to it. Nonetheless, there were times when we paid closer attention – who could forget late 2020 when the TGA declassified low-dose CBD products, allowing them to be obtained in pharmacies without a prescription? We reckon investors would’ve thought we’d see products sold enmasse within months, if the hype around many cannabis stocks was any hint. Obviously that ship has sailed.

Just what is the story with this sector and will it ever become something?

What are the Best ASX Stocks to invest in right now?

Check our buy/sell tips

The reality facing ASX Cannabis Stocks

The big reality is that this is Australia. Unlike more mature markets such as North America or parts of Europe, Australia’s legal cannabis framework has developed cautiously, and that regulatory landscape materially shapes the investment opportunity and risk profile for ASX-listed cannabis companies.

Most ASX cannabis companies are still in early or development stages — focusing on cultivation licences, product approval, clinical evidence generation, export markets, or partnerships rather than mass consumer sales. Capital constraints, regulatory compliance costs, and reliance on specialist prescriber networks can lengthen time to meaningful revenue, which investors should account for when valuing these assets.

The regulatory situation

On the regulatory front, recreational cannabis remains federally illegal throughout Australia, with one narrow exception: the Australian Capital Territory (ACT) has decriminalised personal possession and cultivation of small amounts of cannabis for private use since 2020. But retail sales are still prohibited and federal law continues to override the ACT regime in many respects. This patchwork environment means recreational cannabis markets with regulated retail, tax and distribution channels that have driven valuation expansions in other jurisdictions simply do not exist here yet.

At the federal level, medicinal cannabis was legalised in 2016, and access pathways such as the Therapeutic Goods Administration (TGA) Special Access Scheme and Authorised Prescriber Scheme govern how products reach patients. These frameworks are designed to mitigate risk, ensure clinical oversight and avoid unregulated use — but they also make market entry and commercial scale-up slower and more complex than in less regulated sectors.

A false dawn

As we alluded to earlier, in December 2020, the TGA announced a final decision to amend the Poisons Standard by down-scheduling certain low-dose cannabidiol (CBD) preparations from Schedule 4 (prescription-only medicine) to Schedule 3 (pharmacist-only medicine). This change was intended to allow approved low-dose CBD products to be sold over-the-counter by pharmacists without a prescription.

That sounded promising for patients and, by extension, for investors in ASX cannabis companies developing CBD products — because easier access had the potential to stimulate a genuine consumer market, akin to what was seen in the US or parts of Europe.

However, the practical outcome of that decision has been muted. While the down-scheduling allows low-dose CBD to be sold without a doctor’s prescription, those products still need to be registered on the Australian Register of Therapeutic Goods (ARTG) before they can legally hit pharmacy shelves.

As of early 2026, no CBD products meeting the new Schedule 3 criteria have actually been approved and listed on the ARTG — meaning they haven’t become widely available to consumers. As a result, most “legal access” to medicinal cannabis remains through special access schemes or authorised prescribers, which require doctor involvement and are far less convenient than retail pharmacy distribution.

Have any gotten anywhere?

A few have, but not many, and even those with achievements had setbacks. Cann Group was one of the first movers in the Australian industry, being the first company to be issued a cannabis research licence by the Australian government in 2017 and later receiving Good Manufacturing Practice (GMP) certification to produce medicinal cannabis products at its Mildura facility in Victoria. That licence was expanded to allow the manufacture and release of dried flower products for patient use under Australia’s tightly regulated medicinal frameworks.

Little Green Pharma (ASX:LGP) has been arguably the most consistent. Raised as one of the early Australian companies to cultivate, manufacture and export GMP-standard medicinal cannabis, LGP achieved a significant milestone by being the first Australian producer to export locally grown medicinal cannabis to Europe, beginning with Germany. Over the last few years the company has reported steadily growing revenues, with fiscal year 2025 figures showing about $36.8 million in revenue and positive adjusted EBITDA.

Beyond these, a handful of smaller ASX-listed players have reported revenue growth or clinical trial progress, but overall few companies have transitioned from R&D to sustainable production and profitability. The regulatory environment and cost of compliance have limited the pace of commercialisation relative to early investor optimism.

Conclusion

Investors expecting a guaranteed growth sector amidst ASX Cannabis Stocks have been disappointed and were arguably mistaken to expect anything of the sort. Australia is a less advanced market from a regulatory perspective and many companies have struggled to develop products to hit the market.

The most successful companies have been cultivators rather than developers of drugs or consumer products. It remains to be seen where this sector will go in the future, but there is little reason to expect things will suddenly speed up barring major deregulation, and even then it is no guarantee.